STA Pharmaceutical, a WuXi AppTec Company (WuXi STA) presents a live webcast on Wednesday, May 27, 2020 at 11am EDT | 8am PDT | 4pm BST | 5pm CEST
New drug innovators face key challenges to advance their compound to clinical trials. An investigational new drug (IND) submission is a key milestone for every drug candidate. This webcast will discuss the best practices to advance small-molecule drug candidates quickly from discovery to IND filing, including safety assessment and chemistry, manufacturing, and controls (CMC) programs with real-world case studies.
Key Learning Objectives:
- Key considerations for bringing a drug candidate to Phase I clinical trials
- Best practices for advancing small-molecule drug candidate CMC programs
- A comprehensive roadmap for successful global IND submissions
Who Should Attend:
- Pharmaceutical and biotech companies developing innovator small-molecule compounds (NCE)
- Pharmaceutical and biotech companies aiming for IND submissions
- Program leaders of drug candidate pipelines
- Senior managers and executives from pharmaceutical and biotech companies
- Drug development and pharmaceutical consultants
- Pharmaceutical and biotech venture capitalists and investors
For questions please contact Martha Devia: firstname.lastname@example.org
Philip Jones, PhD
Vice President, Therapeutics Discovery
MD Anderson Cancer Center
Dr. Jones leads a multi-disciplinary team of scientists to identify the next generation of cancer therapies as part of the Moonshot Program®. His team has delivered many drugs to clinical trials and he has contributed towards two approved therapies.
Dr. Jones previously held leadership positions in drug discovery for 15 years at Merck Research Laboratories across the globe before joining MD Anderson in 2011. He received a doctorate in organic chemistry from the University of Nottingham, United Kingdom, and completed post- doctoral research at Philipps-Universitat Marburg, Germany.
Cliff Yin, PhD
Executive Director of CMC Project Management, STA Pharmaceutical
WuXi AppTec Company (WuXi STA)
Dr. Yin is the executive director of CMC project management at WuXi STA. His team provides support for WuXi STA’s Integrated CMC platform, developing novel therapies to reach patients faster.
Dr. Yin previously held various leadership positions in API development, clinical supply chain management and clinical project management for 12 years at Novartis before joining WuXi STA in 2019. He received a doctorate in organic chemistry and completed post-doctoral research from Auburn University.
Xin Zhang, PhD
Vice President, Head of Integrated Services, Laboratory Testing Division
Dr. Xin Zhang leads the lab testing division for WuXi AppTec on strategic project and customer experience management, focusing on establishing an ecosystem of cross-division partnership and industry alliances while engaging in commercial operation.
Prior to WuXi, Dr. Zhang served in senior management roles in Charles River Laboratories, Lab Corp (Tandem Labs) and Agilux Labs. His experience spans various fields focusing on establishing the client-oriented operational structure, multi-functional management, business strategies, and implementation.
Dr. Xin Zhang received a doctorate in organic chemistry from the University of Iowa and his undergraduate degree from Peking University.